Nearly all adults who lose less than 5% of their body weight with tirzepatide at 12 weeks were able to achieve at least a 5% weight loss by 72 weeks, according to a post-hoc analysis of the SURMOUNT-1 trial.
A randomized controlled trial comprised of adults with obesity and prediabetes found that both time-restricted eating and a usual eating pattern resulted in weight loss when calories were held constant in both groups.
Apple cider vinegar might be an effective dietary intervention in the management of obesity, results from a randomized clinical study showed.
The 32,000 people who finished the program in the first year saw an average weight loss of 2.2 kilos (5lbs); with those who attended more (at least 60%) of the program losing an average of 3.9 kilos (8.5lbs).
Endoscopic sleeve gastroplasty was more cost-effective and sustained greater weight loss over 5 years compared with semaglutide for patients with class II obesity.
